Replies to post #503247 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

[quoteIf you are interested, you should compare OS of mesenchymal GBMs between the crossovers and the treatment][/quote]

Maybe the JA will present this comparison. Right now I am already fairly certain that when compared to the initial GBM tumors, the recurrent tumors have stronger mesenchymal signatures which makes them more vulnerable to the immunological impact of the vaccine. No wonder that the crossover group most likely outperformed the Treatment group.